WNT1 and hepatocellular carcinoma: Yiqi Liangxue Jiedu Prescription (YLJP), which has been authorised by the national patent (No. ZL202110889980.5) for the prevention and treatment of HCC, can inhibit the classical Wnt pathway by decreasing the expression of Wnt1 and β-catenin, and inhibit the value-adding and cancerous transformation of HOC (Hepatocellular Originated Pre-cancer Cells), thus suppressing the occurrence of HCC.